Medpace (MEDP) Stock Insights

MEDP$656.77—
Medical - Diagnostics & ResearchLarge CapGrowth StockHigh Quality
Compare
Market cap$17.08BEnterprise value—Revenue (TTM)$2.84BMarket positionTop 25%

Score

49
Neutral
Value
18
Quality
68
Growth
60

Insights

  • Revenue by product
Revenue by product
PeriodValue
FY2018Antiviral And Anti Infective: 76739000.0, Cardiology: 91824000.0, Central Nervous System: 53904000.0, Endocrine: 26002000.0, Medical Devices: 11772000.0, Metabolic: 94128000.0, Oncology: 189026000.0, Other: 161194000.0, Revenue Net: 15100000.0
FY2019Antiviral And Anti Infective: 86390000.0, Cardiology: 91258000.0, Central Nervous System: 65391000.0, Direct Revenue: 0.0, Metabolic: 138650000.0, Oncology: 256766000.0, Other: 222514000.0, Reimbursed Out Of Pocket Revenue: 0.0, Revenue Net: 18900000.0
FY2020Revenue Net: 15900000.0
FY2021Antiviral And Anti Infective: 110976000.0, Cardiology: 119692000.0, Central Nervous System: 121548000.0, Metabolic: 159900000.0, Oncology: 362846000.0, Other: 267415000.0, Revenue Net: 34500000.0
FY2022Antiviral And Anti Infective: 118031000.0, Cardiology: 174634000.0, Central Nervous System: 157939000.0, Metabolic: 244682000.0, Oncology: 467796000.0, Other: 296914000.0, Revenue Net: 1459996000.0
FY2023Antiviral And Anti Infective: 163312000.0, Cardiology: 193690000.0, Central Nervous System: 160057000.0, Metabolic: 376842000.0, Oncology: 587097000.0, Other: 404844000.0, Revenue Net: 1885842000.0
FY2024Antiviral And Anti Infective: 156460000.0, Cardiology: 230454000.0, Central Nervous System: 181977000.0, Metabolic: 457542000.0, Oncology: 651237000.0, Other: 431384000.0
FY2025Antiviral And Anti Infective: 134935000.0, Cardiology: 239371000.0, Central Nervous System: 254838000.0, Metabolic: 744957000.0, Oncology: 747585000.0, Other: 408548000.0

Medpace (MEDP) Stock Insights

MEDP price $656.77 —

Ticker
MEDP
Price
$656.77
Change
—
Market cap
$17.08B
P/E
34.25
Forward P/E
32.88
Dividend yield
0.00%
Beta
1.12
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Stocklytics score
49
Value
18
Quality
68
Growth
60

Stocklytics score rationale: value 18, quality 68, growth 60.

AI Score 75. Medpace Holdings, Inc. has a strong market capitalization of approximately $18.24 billion and solid profit margins, including a net profit margin of 18.2%

Insights

Revenue by product
PeriodValue
FY2018Antiviral And Anti Infective: 76739000.0, Cardiology: 91824000.0, Central Nervous System: 53904000.0, Endocrine: 26002000.0, Medical Devices: 11772000.0, Metabolic: 94128000.0, Oncology: 189026000.0, Other: 161194000.0, Revenue Net: 15100000.0
FY2019Antiviral And Anti Infective: 86390000.0, Cardiology: 91258000.0, Central Nervous System: 65391000.0, Direct Revenue: 0.0, Metabolic: 138650000.0, Oncology: 256766000.0, Other: 222514000.0, Reimbursed Out Of Pocket Revenue: 0.0, Revenue Net: 18900000.0
FY2020Revenue Net: 15900000.0
FY2021Antiviral And Anti Infective: 110976000.0, Cardiology: 119692000.0, Central Nervous System: 121548000.0, Metabolic: 159900000.0, Oncology: 362846000.0, Other: 267415000.0, Revenue Net: 34500000.0
FY2022Antiviral And Anti Infective: 118031000.0, Cardiology: 174634000.0, Central Nervous System: 157939000.0, Metabolic: 244682000.0, Oncology: 467796000.0, Other: 296914000.0, Revenue Net: 1459996000.0
FY2023Antiviral And Anti Infective: 163312000.0, Cardiology: 193690000.0, Central Nervous System: 160057000.0, Metabolic: 376842000.0, Oncology: 587097000.0, Other: 404844000.0, Revenue Net: 1885842000.0
FY2024Antiviral And Anti Infective: 156460000.0, Cardiology: 230454000.0, Central Nervous System: 181977000.0, Metabolic: 457542000.0, Oncology: 651237000.0, Other: 431384000.0
FY2025Antiviral And Anti Infective: 134935000.0, Cardiology: 239371000.0, Central Nervous System: 254838000.0, Metabolic: 744957000.0, Oncology: 747585000.0, Other: 408548000.0

Insights · Forecast · Financials · Learn

Stocklytics home · Screener